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Relapse is common after hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia
(ALL). Although 1200 cGy total body irradiation (TBI) and cyclophosphamide (Cy) is the standard conditioning
regimen, attempts to reduce relapse have led to the addition of a second chemotherapeutic agent and/or
higher dose of TBI. We examined HSCT outcomes in patients age <18 years with ALL, in second or subsequent
remission or in relapse at transplantation. Most transplantations were performed with the patient in
remission. Patients received grafts from an HLA-matched sibling or unrelated donor. Four treatment groups
were created: (1) Cy þ TBI  1200 cGy (n ¼ 304), (2) Cy þ etoposide þ TBI  1200 cGy (n ¼ 108), (3)
Cy þ TBI  1300 cGy (n ¼ 327), and (4) Cy þ etoposide þ TBI  1300 cGy (n ¼ 26). Neither TBI > 1200 cGy nor
the addition of etoposide resulted in fewer relapses. The 5-year probability of relapse was 30% for group 1,
28% for group 2, 35% for group 3, and 31% for group 4. However, transplantation-related mortality was higher
(35% versus 25%, P ¼ .02) and overall survival lower (36% versus 48%, P ¼ .03) in group 4 compared
with group 3. Our ﬁndings indicate that compared with the standard regimen, neither TBI > 1200 cGy nor the
addition of etoposide improves survival after HSCT for ALL.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION cGyþ Cy, and (4) TBI 1320-1400 cGyþ Cyþ etoposide. In the
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an accepted treatment for children with recurrent
acute lymphoblastic leukemia (ALL) [1-3]. Transplantation
conditioning regimens typically consist of total body irradia-
tion (TBI), in doses ranging from1000 to 1400 cGy, alongwith
one or more chemotherapeutic agents. The standard condi-
tioning regimen, developed based on empirical observations,
is cyclophosphamide (Cy) 120 mg/kg and TBI 1200 cGy [4].
The Center for International Blood and Marrow Transplant
Research (CIBMTR) has reported that noneirradiation-
containing regimens are associated with higher relapse
rates compared with TBI-containing regimens for ALL [5].
Attempts to decrease the risk of relapse after HCT by modu-
lating transplantation conditioning have included increasing
the TBI dose to >1200 cGy and/or adding a second chemo-
therapeutic agent, most commonly etoposide [6-8]. Others
have attempted to decrease the intensity of the conditioning
regimen, relying on immune modulation (ie, graft-versus-
leukemia effect) for disease control [9]. Although reports on
relatively few patients suggest acceptable leukemia-free
survival, these regimens are used in <5% of HSCTs for pedi-
atric ALL [10].
A review of myeloablative TBI-containing conditioning
regimens for pediatric ALL reported to the CIBMTR identiﬁed
4 commonly used regimens: (1) TBI 1000 or 1200 cGy þ Cy,
(2) TBI 1000 or 1200 cGyþ Cyþ etoposide, (3) TBI 1320-1400dgments on page 259.
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12.09.019present analysis, we sought to examine the effect of these 4
commonly used transplantation conditioning regimens on
leukemia relapse, transplantation-related mortality, and
overall survival in 765 children and adolescents with ALL.
PATIENTS AND METHODS
Data Source
The CIBMTR is a voluntary working group of more than 400 transplant
centers worldwide that contribute detailed data on consecutive allogeneic
and autologous HSCT to a statistical center at the Medical College of Wis-
consin in Milwaukee or the National Marrow Donor Program Coordinating
Center in Minneapolis. Participating centers are required to report all HSCTs
consecutively; compliance is monitored by onsite audits. Patients are fol-
lowed longitudinally. All patients and/or their guardians provide written
informed consent. The Institutional Review Boards of the Medical College of
Wisconsin and the National Marrow Donor Program approved this study.
Inclusion Criteria
This study included patients with ALL age <18 years at the time of
HSCT who received a graft from an HLA-matched sibling or an unrelated
donor. Unrelated donor grafts included bone marrow and umbilical cord
blood. All HSCTs were performed between 1998 and 2007. All patients
received myeloablative conditioning with a TBI-containing regimen
(TBI  1000 cGy). Recipients of noneTBI-containing regimens were
excluded.
Outcomes
The primary study outcomewas relapse after HSCT. Relapse was deﬁned
asmorphological reappearance of leukemic blasts. Other outcomes included
transplantation-related mortality, deﬁned as death not related to leukemia
recurrence, and overall survival, deﬁned as death from any cause. Surviving
patients were censored at last follow-up.
Statistical Analysis
Patient, disease, and transplant characteristics of the 4 treatment
groups were compared using the c2 test for categorical variables. The
probability of overall survival was calculated with the Kaplan-Meier
estimator [11]. The probabilities of transplantation-related mortality andTransplantation.
Table 1
Patient, Disease, and Transplant Characteristics
Cy Cy þ Etoposide P Value
TBI  1200 cGy TBI  1320 cGy TBI  1200 cGy TBI  1320 cGy
Number 304 327 108 26
Age at HSCT, years, n (%) NS
10 171 (56) 197 (60) 71 (66) 14 (54)
11-18 133 (44) 130 (40) 37 (34) 12 (46)
Sex, n (%) NS
Male 200 (65) 214 (65) 66 (61) 14 (54)
Female 104 (32) 113 (35) 42 (39) 12 (46)
Performance score, n (%) <.0001
<90% 47 (15) 40 (12) 28 (26) 8 (31)
90% 244 (80) 253 (77) 78 (72) 17 (65)
Not reported 13 (4) 34 (10) 2 (2) 1 (4)
Recipient cytomegalovirus status, n (%) .002
Positive 169 (56) 145 (45) 35 (32) 11 (42)
Negative 133 (44) 177 (54) 71 (66) 15 (58)
Not reported 2 (1) 5 (1) 2 (2) __
National Cancer Institute risk score, n (%) NS
Normal 105 (35) 124 (38) 47 (44) 8 (26)
High 164 (54) 152 (46) 47 (44) 16 (58)
Not reported 35 (12) 51 (16) 14 (13) 2 (16)
Cytogenetic risk group, n (%) NS
Intermediate risk 231 (76) 229 (70) 81 (75) 13 (50)
High risk 10 (3) 17 (5) 2 (2) 3 (12)
Not reported 63 (21) 81 (25) 25 (23) 10 (38)
Duration of ﬁrst remission, n (%) NS
36 months 201 (66) 213 (65) 66 (61) 17 (65)
>36 months 103 (34) 114 (35) 42 (39) 9 (35)
Disease status, n (%) NS
Second complete remission 227 (75) 219 (67) 78 (72) 16 (62)
Third complete remission 55 (18) 71 (22) 21 (19) 5 (19)
Relapse 22 (7) 37 (11) 9 (8) 5 (19)
Donor source, n (%) <.0001
HLA-matched sibling
Bone marrow 103 (34) 19 (6) 15 (14) 10 (38)
Cord blood 4 (1) 6 (2) 3 (3) 1 (4)
Unrelated
Matched 47 (15) 66 (20) 18 (17) 4 (15)
Mismatched 82 (27) 106 (32) 29 (27) 10 (38)
Cord blood 68 (22) 132 (40) 42 (39) 3 (12)
Graft-versus-host disease prophylaxis, n (%) <.0001
Cyclosporine þ methotrexate 186 (61) 139 (43) 56 (52) 11 (42)
Cyclosporine  steroid 77 (25) 124 (38) 26 (24) 13 (50)
Tacrolimus þ methotrexate 32 (11) 54 (17) 15 (14) 0 (0)
Tacrolimus  other 4 (1) 7 (2) 6 (6) 1 (4)
Methotrexate þ other 5 (2) 3 (1) 5 (5) 1 (4)
Year of transplantation, n (%) <.0001
1998-1999 73 (24) 41 (13) 30 (28) 10 (38)
2000-2004 160 (53) 173 (53) 56 (52) 14 (54)
2005-2007 71 (23) 113 (35) 22 (20) 2 (8)
Follow-up of surviving patients; median (range), months 50 (3-133) 44 (2-119) 46 (3-130) 53 (34-93)
NS indicates not signiﬁcant.
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transplantation-related mortality, relapse was the competing event, and for
relapse, transplantation-related mortality was the competing event. Log-
transformation was used to derive 95% conﬁdence intervals (CIs). Multi-
variate models were built using Cox proportional hazards regression models
for transplantation-related mortality, relapse, and overall mortality [13].
Models were built using the backward stepwise selection procedure and
conﬁrmed using the forward stepwise selection procedure. The proportional
hazards assumption was tested for each variable individually; all variables
met this assumption. A P value .05 was considered statistically signiﬁcant.
The variables for transplantation conditioning regimendTBI  1200
cGy (1000 or 1200 cGy) þ Cy versus TBI  1200 cGy þ Cy þ etoposide
versus TBI  1320 (1320 or 1350 or 1400 cGy) þ Cy versus
TBI  1320 þ Cy þ etoposidedwere included in all steps of model building
regardless of the level of signiﬁcance. Other variables testedwere included in
the ﬁnal model when signiﬁcant; these included patient age (10 years
versus >10 years), National Cancer Institute risk score (standard risk versus
high risk), cytogenetic risk (standard risk versus high risk), duration of ﬁrst
remission (36months versus>36months), patient performance score (90-
100 versus 80), donor and graft source (HLA-matched sibling [bone
marrow/cord blood] versus HLA-matched unrelated donor bone marrow
versus HLA-mismatched unrelated donor bone marrow versus unrelatedcord blood), recipient cytomegalovirus serostatus (positive versus negative),
and year of transplantation (1998-1999 versus 2000-2004 versus 2005-
2007). There was no signiﬁcant effect of transplantation center on survival.
All analyses were performed using SAS 9.1 (SAS Institute, Cary, NC).RESULTS
Patient, Disease, and Transplant Characteristics
Patient, disease, and transplant characteristics by treat-
ment group are presented in Table 1. Sixteen of 412 patients
(4%) who received TBI  1200 cGy were given 1000 cGy, and
the remaining patients were given TBI 1200 cGy. Eighty-four
of the 353 patients (24%) who received TBI  1320 cGy were
given 1320 cGy, 145 (41%) were given 1350 cGy, and 124
(35%) were given 1400 cGy. Almost all patients received Cy
120 mg/kg regardless of TBI dose; 87% of those who received
etoposide as a second agent received either 40 mg/kg or
60 mg/kg. Although there were no signiﬁcant differences in
patient age among the 4 treatment groups, patients who
Table 2
Results of Multivariate Analysis
HR (95% CI) P Value
Relapse
TBI  1200 cGy þ Cy þ etoposide
versus TBI  1200 cGy þ Cy
0.97 (0.63-1.48) .87
TBI  1320 cGy þ Cy þ etoposide
versus TBI  1320 cGy þ Cy
1.01 (0.49-2.09) .97
TBI  1320 cGy þ Cy versus
TBI  1200 cGy þ Cy
1.13 (0.85-1.50) .41
TBI  1320 cGy þ Cy þ etoposide
versus TBI  1200 cGy þ Cy þ
etoposide
1.19 (0.54-2.61) .67
Transplantation-related mortality
TBI  1200 cGy þ Cy þ etoposide
versus TBI  1200 cGy þ Cy
1.06 (0.70-1.60) .78
TBI  1320 cGy þ Cy þ etoposide
versus TBI  1320 cGy þ Cy
2.36 (1.17-4.76) .02
TBI  1320 cGy þ Cy versus
TBI  1200 cGy þ Cy
0.73 (0.53-1.01) .06
TBI  1320 cGy þ Cy þ etoposide
versus TBI  1200 cGy þ Cy þ
etoposide
1.63 (0.77-3.45) .20
Overall mortality
TBI  1200 cGy þ Cy þ etoposide
versus TBI  1200 cGy þ Cy
1.10 (0.82-1.50) .52
TBI  1320 cGy þ Cy þ etoposide
versus TBI  1320 cGy þ Cy
1.79 (1.07-2.99) .03
TBI  1320 cGy þ Cy versus
TBI  1200 cGy þ Cy
0.87 (0.69-1.09) .23
TBI  1320 cGy þ Cy þ etoposide
versus TBI  1200 cGy þ Cy þ
etoposide
1.40 (0.81-2.43) .23
Figure 1. Probability of relapse by conditioning regimen. Group 1: TBI  1200
cGy þ Cy; group 2: TBI  1200 cGy þ Cy þ etoposide; group 3: TBI  1300
cGy þ Cy; group 4: TBI  1300 cGy þ Cy þ etoposide.
Figure 2. Probability of transplantation-related mortality by conditioning
regimen. Group 1: TBI  1200 cGy þ Cy; group 2: TBI  1200
cGy þ Cy þ etoposide; group 3: TBI  1300 cGy þ Cy; group 4: TBI  1300
cGy þ Cy þ etoposide.
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to have a performance score <90. Disease characteristics,
including National Cancer Institute risk score, cytogenetic
risk, time from diagnosis to transplantation, and disease
status at transplantation, were similar across the treatment
groups. There were differences among the groups in the
choice of conditioning regimen; recipients of TBI 
1320 þ Cy þ etoposide (group 4) were more likely to have
received an HLA-matched sibling transplant, less likely to
have received an umbilical cord blood transplant, more likely
to have received methotrexate-containing graft-versus-host
disease prophylaxis, and more likely to have undergone
HSCT before 2005. The median follow-up of surviving
patients in all treatment groups was 4 years.
Relapse
In multivariate analysis, the risk of relapse was similar
among the 4 treatment groups (Table 2). The 5-year proba-
bility of relapse was 30% (95% CI, 25%-35%) for group 1, 28%
(95% CI, 19%-37%) for group 2, 35% (95% CI, 29%-40%) for
group 3, and 31% (95% CI, 15%-48%) for group 4 (Figure 1).
Relapse risk was similar in patients receiving TBI
(any dose) þ Cy þ etoposide and those receiving TBI
(any dose) þ Cy (hazard ratio [HR], 0.9; 95% CI, 0.66-1.34;
P ¼ .72). However, relapse risk was associated with
patient sex, duration of ﬁrst remission, and disease status at
transplantation, with higher risk in females (HR, 1.5; 95% CI,
1.2-2.0; P ¼ .003), patients with ﬁrst remission lasting less
than 36 months (HR, 2.96; 95% CI, 2.13-4.17; P < .001),
and patients in third complete remission or relapse at the
time of transplantation (HR, 1.6; 95% CI, 1.2-2.2; P ¼ .001).
Transplantation-Related Mortality
The risk of transplantation-related mortality differed by
conditioning regimen (Table 2). Compared with recipients ofTBI  1320 cGy þ Cy (group 3), those who received
TBI  1320 cGy þ Cy þ etoposide (group 4) were at greater
risk for transplantation-related mortality. The addition of
etoposide to TBI  1200 cGy þ Cy (group 2) was not associ-
ated with increased risk compared with TBI 1200 cGyþ Cy
alone (group 1) (HR, 1.06; 95% CI, 0.70-1.60; P ¼ .78). The
5-year cumulative incidence of transplantation-related
mortality was 25% (95% CI, 21%-31%) for group 1, 32% (95%
CI, 23%-41%) for group 2, 25% (95% CI, 20%-30%) for group 3,
and 35% (95% CI, 18%-52%) for group 4 (Figure 2). The risk of
transplantation-related mortality was not higher in recipi-
ents of TBI (any dose) þ Cy þ etoposide compared
with recipients of TBI (any dose) þ Cy (HR, 1.37; 95% CI,
0.97-1.92; P ¼ .07). Age >10 years (HR, 1.93; 95% CI, 1.45-
2.56; P < .001) was associated with a higher risk of
transplantation-related mortality. Compared with recipients
of an HLA-matched sibling transplant, the risk of
transplantation-relatedmortality was greater in recipients of
matched unrelated donor bone marrow (HR, 3.26; 95% CI,
1.77-6.02; P < .001), mismatched unrelated donor bone
marrow (HR, 4.07; 95% CI, 2.34-7.08; P < .001), and
umbilical cord blood (HR, 5.30; 95% CI, 3.04-9.25; P < .001)
transplants.
Overall Survival
Overall mortality risk also differed by transplantation
conditioning regimen (Table 2). Recipients of TBI  1320 cGy
who received Cy þ etoposide had a higher mortality risk
compared with those who received Cy alone. However,
mortality risk was not higher in recipients of TBI  1200 cGy
Figure 3. Probability of overall survival by conditioning regimen adjusted for
patient age, duration of ﬁrst complete remission, disease status at trans-
plantation, and donor HLA match. Group 1: TBI  1200 cGy þ Cy; group
2: TBI  1200 cGy þ Cy þ etoposide; group 3: TBI  1300 cGy þ Cy; group
4: TBI  1300 cGy þ Cy þ etoposide.
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received Cy alone (HR, 1.10; 95% CI, 0.82-1.50; P ¼ .52).
Overall mortality risk was not higher in recipients of TBI
(any dose) þ Cy þ etoposide compared with recipients of TBI
(any dose) þ Cy (HR, 1.24; 95% CI, 0.96-1.59; P ¼ .09).
Mortality risk was higher in patients age >10 years (HR,
1.05; 95% CI, 1.22-1.85; P < .001), those with a duration of
ﬁrst remission 36 months (HR, 1.69; 95% CI, 1.35-2.11;
P < .001), and those undergoing HSCT in third remission
or in relapse (HR, 1.41; 95% CI, 1.14-1.74; P¼ .002). Compared
with recipients of HLA-matched sibling transplants, overall
mortality risk was higher in recipients of mismatched
unrelated donor bone marrow (HR, 1.72; 95% CI, 1.27-2.34;
P < .001) and umbilical cord blood (HR, 1.87; 95% CI, 1.36-
2.57; P < .001) transplants, but not in recipients of matched
unrelated donor bone marrow transplants (HR, 1.34; 95% CI,
0.94-1.92; P ¼ .11). The 5-year probability of overall survival
was 44% (95% CI, 38%-50%) for group 1, 40% (95% CI, 30%-50%)
for group 2, 48% (95% CI, 42%-54%) for group 3, and 36% (95%
CI, 19%-53%) for group 4 (Figure 3).DISCUSSION
In the present analysis, we examined for an effect on
relapse after HSCT from different TBI-containing myeloa-
blative conditioning regimens in children and adolescents
with ALL. The patients were divided into 4 groups based on
TBI dose and chemotherapeutic agents. Neither TBI  1200
cGy nor the addition of etoposide to Cy was associated with
decreased risk of relapse. However, transplantation-related
and overall mortality risks were higher with TBI  1320
cGy þ Cy þ etoposide compared with TBI  1320 cGy þ Cy
alone. In patients receiving lower-dose TBI (1000 or 1200
cGy), the addition of etoposide was not associated with
increased mortality risk.
The addition of a second chemotherapeutic agent for
children and adolescents receiving myeloablative TBI-based
conditioning for enhanced leukemia control is not sup-
ported by these data. On the contrary, the addition of
a second chemotherapeutic agent to a TBI  1320 cGy þ Cy
regimen increases the risk of mortality and should be
avoided.
Our observations are in contrast with the ﬁndings of
Duerst et al. [14] in their study of 41 children with ALL and
abute myelogenous leukemia conditioned with TBI 1200-
1400 cGy þ Cy þ etoposide. Duerst et al. observed a singlefatal regimen-related toxicity in their series, and recurrent
leukemia was the predominant cause of treatment failure. In
that study, the etoposide dose was 30 mg/kg, whereas in the
present study, most patients (87%) received an etoposide
dose >30 mg/kg. The difference in mortality risk between
the present study and the study of Deurst et al. may be
related to the different etoposide doses. Because only 17 of
our patients received a dose of 30 mg/kg, we were unable to
test for an effect of etoposide dose on mortality risk. Others
have reported a decreased risk of relapse with regimens
consisting of TBI and etoposide alone. For example, a large
series from the CIBMTR [15] that compared TBI dose (<1300
cGy versus 1300 cGy) with Cy or etoposide in children and
adults with ALL in ﬁrst or second complete remission found
that for patients in second complete remission, relapse and
mortality risks were lower in those who received TBI (any
dose) and etoposide compared with those who received
TBI < 1300 cGy and Cy. In an ongoing clinical trial conducted
by the International Berlin-Frankfurt-Muenster group for
allogeneic HSCT in children and adolescents with ALL
(NCT01423747), the recommended regimen is TBI 1200 cGy
and etoposide 60 mg/kg for recipients of matched related
and unrelated donor grafts and etoposide 40 mg/kg for
recipients of mismatched related and unrelated donor grafts.
We were unable to test for an effect of TBI þ etoposide alone
versus TBI þ Cy alone, because our study cohort contained
too few children who received etoposide alone. In another
study focusing on pediatric ALL, Gassas et al. [8] compared
the addition of etoposide or Cy to TBI 1200 cGy and
concluded that both regimens were equally effective. We
tested for an effect when etoposide was added to the TBI 
1200 cGy þ Cy regimen, and found none. It is plausible that
the excess mortality risk observed with the addition of eto-
poside to higher-dose TBI is a result of the additive effect of
higher-dose TBI and a second chemotherapeutic agent.
Although the actual etiology behind the excess mortality
is unknown, our observations suggest that neither a TBI
dose >1200 cGy nor the addition of a second chemothera-
peutic agent is necessary.
Several factors besides conditioning regimen are associ-
ated with leukemia relapse. Consistent with other reports
[16], duration of ﬁrst remission and disease status at trans-
plantationwere important predictors of relapse in our series.
We found no signiﬁcant difference in relapse risk with the
addition of etoposide. Our ﬁndings are in contrast with
a previous report indicating that TBI-containing regimens
with etoposide alone were associated with superior
leukemia control posttransplantation [15]. Patient age varies
among studies, however, with our series limited to children
and adolescents, and the reported differences in risk may be
related to differences in the biology of pediatric and adult
ALL and/or differences in intensity of up-front chemotherapy
regimens used to induce a second remission.
In the present study, along with conditioning regimen,
patient age and donor source also affected survival. Older age
and transplantation of unrelated donor grafts were associ-
ated with higher mortality risk. Although they predict
mortality, patient age and donor source are not modiﬁable
factors. The data presented herein span the period 1998-
2007. Concurrent with improvements in supportive care and
donor selection, survival rates are not different after HLA-
matched sibling and matched unrelated donor trans-
plantation [17]. In the absence of a suitably matched related
donor, physicians should defer to recommended guidelines
for selection of unrelated donors, that is, transplantation of
J. Tracey et al. / Biol Blood Marrow Transplant 19 (2013) 255e259 259bone marrow from an 8/8 or a 7/8 HLA-matched adult donor
or a mismatched umbilical cord blood unit with an adequate
cell dose [18]. Of note, in our series, the effect of conditioning
regimen on transplantation-related and overall mortality
was independent of patient age and donor source. Patients
who received TBI  1320 cGy þ Cy þ etoposide were more
likely to have a performance score <90. Because poor
performance score predicts survival, this variable was
retained in the ﬁnal multivariate model, implying that the
observed adverse effect on mortality is independent of
performance score.
In the present study, as in any study using data collected
by a registry, several unknown or unmeasured factors also
might have inﬂuenced outcomes. However, we performed
a carefully controlled analysis adjusting for patient, disease,
and transplant characteristics known to be associated with
leukemia relapse and survival after HSCT. Our ﬁndings
suggest that the addition of etoposide to a TBI  1320
cGy þ Cy conditioning regimen increases mortality risk and
should be avoided in children and adolescents with ALL.
Given the known higher risk of second malignant neoplasm
with a TBI dose 1300 cGy [19,20], in the absence of data
that demonstrate an advantage for either lower relapse or
higher survival, a TBI dose >1200 cGy should be avoided in
children with ALL.
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